ArticleHemaSphere2024
Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia.
Mei-Jing Liu, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chong-Sheng Qian, Sheng-Li Xue, Hai-Ping Dai, Wen-Jie Gong
Open access · goldAbstract read
In one paragraphArticle in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 1 institution in 2 countries.
Mei-Jing LiuNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Kai-Wen TanNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Han-Yu CaoNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Si-Man HuangNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Chong-Sheng QianNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Sheng-Li XueNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Hai-Ping DaiNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.
Wen-Jie GongNational Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China.ORCID 0000-0001-6965-6209 Soochow University · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID38435426
PMCPMC10897941
OpenAlexW4392203024
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390